|
1
|
Application of surface plasmon resonance imaging biosensors for determination of fibronectin, laminin-5 and type IV collagen in serum of transitional bladder cancer patients. J Pharm Biomed Anal 2023; 222:115103. [DOI: 10.1016/j.jpba.2022.115103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/03/2022] [Accepted: 10/07/2022] [Indexed: 11/06/2022]
|
|
2
|
Sevillano Fernández E, Madurga de Lacalle R, Rodriguez Moreno JF, Barquín García A, Yagüe Fernández M, Navarro Alcaraz P, Barba Llacer M, Quiralte Pulido M, García-Donás Jiménez J. Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients. J Clin Med 2022; 11:jcm11154483. [PMID: 35956100 PMCID: PMC9369263 DOI: 10.3390/jcm11154483] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 07/23/2022] [Accepted: 07/27/2022] [Indexed: 02/01/2023] Open
Abstract
Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable target, key to the pathogenesis of some urothelial cancers (UCs). Though FGFR GAs are common in noninvasive UC, little is known about their role in the metastatic(m) setting and response to therapy. This study aimed to assess the impact of FGFR alterations on sensitivity to systemic treatments and survival and to validate Bajorin’s and Bellmunt’s prognostic scores in mUC patients according to their FGFR status. We retrospectively analyzed data from 98 patients with tumor-sequenced UC who received treatment between January 2010 and December 2020. Up to 77 developed metastatic disease and were deemed the study population. Twenty-six showed FGFR GAs. A trend toward a better response to cisplatin and checkpoint inhibitors was suggested favoring FGFR GA tumors. FGFR GA patients who received an FGFR inhibitor as first-line had poorer responses compared with other options (20% vs. 68.4%, p = 0.0065). Median PFS was 6 vs. 5 months in the FGFR GA vs. FGFR WT cohort (p = 0.71). Median OS was significantly worse in the FGFR GA vs. FGFR WT cohort (16.2 vs. 31.9 months, p = 0.045). Multivariate analyses deemed FGFR GAs as a factor independently associated with the outcome (HR 2.59 (95% CI 1.21–5.55)). Bajorin’s model correctly predicted clinical outcomes in the whole study population but not in FGFR GA cases. FGFR GAs are a relevant biomarker in mUC that could condition the response to systemic therapy. New prognostic models, including this molecular determination, should be designed and validated.
Collapse
Affiliation(s)
- Elena Sevillano Fernández
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
- Departamento de Oncología Médica, Hospital Sanchinarro, Universidad San Pablo-CEU, CEU Universities, 28003 Madrid, Spain
- Correspondence:
| | | | - Juan Francisco Rodriguez Moreno
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
| | - Arantzazu Barquín García
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
| | - Mónica Yagüe Fernández
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
| | - Paloma Navarro Alcaraz
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
| | - María Barba Llacer
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
| | - Miguel Quiralte Pulido
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
| | - Jesús García-Donás Jiménez
- HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain; (J.F.R.M.); (A.B.G.); (M.Y.F.); (P.N.A.); (M.B.L.); (M.Q.P.); (J.G.-D.J.)
- Departamento de Oncología Médica, Hospital Sanchinarro, Universidad San Pablo-CEU, CEU Universities, 28003 Madrid, Spain
| |
Collapse
|